Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $143.9 million.

  • Arcutis Biotherapeutics' Short-term Investments fell 2644.83% to $143.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.9 million, marking a year-over-year decrease of 2644.83%. This contributed to the annual value of $156.6 million for FY2024, which is 1463.13% down from last year.
  • Arcutis Biotherapeutics' Short-term Investments amounted to $143.9 million in Q3 2025, which was down 2644.83% from $118.1 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Short-term Investments' 5-year high stood at $395.4 million during Q3 2022, with a 5-year trough of $118.1 million in Q2 2025.
  • In the last 5 years, Arcutis Biotherapeutics' Short-term Investments had a median value of $213.8 million in 2024 and averaged $226.2 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Short-term Investments skyrocketed by 51079.94% in 2021, and later crashed by 6974.31% in 2023.
  • Arcutis Biotherapeutics' Short-term Investments (Quarter) stood at $290.6 million in 2021, then increased by 22.48% to $355.9 million in 2022, then tumbled by 48.46% to $183.5 million in 2023, then decreased by 14.63% to $156.6 million in 2024, then dropped by 8.09% to $143.9 million in 2025.
  • Its last three reported values are $143.9 million in Q3 2025, $118.1 million for Q2 2025, and $145.0 million during Q1 2025.